Turn Biotechnologies Launches Groundbreaking Study on ERA™ Therapy for Bone Marrow Restoration and Effectiveness

Turn Biotechnologies Sets Sights on Bone Marrow Rejuvenation



In an exciting development for the field of regenerative medicine, Turn Biotechnologies, a company specializing in cellular rejuvenation, recently announced an innovative study aimed at evaluating the efficacy of their pioneering ERA™ therapy for the restoration of bone marrow function. This move comes as part of their ongoing commitment to addressing age-related diseases that currently lack effective treatments.

Leveraging mRNA technology, Turn Biotechnologies seeks to enhance the quality of donor cells in stem cell transplants, which is crucial for improving patient outcomes. Conducted in partnership with the Methuselah Foundation, this study marks a significant step towards understanding how epigenetic reprogramming can rejuvenate bone marrow stem cells. As age progresses, individuals experience a decline in bone marrow output of essential immune cells, such as B and T cells, that combat diseases and inflammation. Furthermore, aged stem cells are often plagued with alterations to their DNA, potentially leading to serious conditions like leukemia.

Dr. Timothy Olson, MD, PhD, the lead investigator of the study and medical director at the Children's Hospital of Philadelphia, emphasizes the importance of this research: _“Multiple studies have shown that patients receiving younger donor stem cells tend to have better outcomes. We are hopeful that our findings will demonstrate that epigenetic reprogramming can make bone marrow transplants both more effective and accessible.”_

The study aims to rejuvenate donor stem cells, potentially increasing the safety and efficacy of these intensive treatments. Achieving this rejuvenation could not only enhance the body’s capacity to fight diseases but also accelerate wound healing and improve oxygen transport by red blood cells. Ultimately, this may allow for the use of older donors in transplant scenarios, a substantial shift in current medical practice.

David Gobel, co-founder and CEO of the Methuselah Foundation, expresses optimism about the potential impact of the study, stating that it could be crucial in extending the healthy human lifespan: _“We believe this study will validate that epigenetic reprogramming can effectively rejuvenate bone marrow cells and restore their youthful functionality.”_

Over the course of a year, the study will utilize mouse models to evaluate the effects of the ERA solution on blood progenitor cells treated in accordance with the study’s protocols. These treated cells will subsequently be transplanted into irradiated mice sharing the same genetic background, allowing for an accurate assessment of the efficacy of the treatment.

Anja Krammer, CEO of Turn Biotechnologies, highlighted the broader implications of the research, remarking: _“This study represents a significant milestone for our company as it illustrates our ability to apply our scientific discoveries beyond singular therapeutics to develop robust solutions for various diseases. We are optimistic that it will affirm the remarkably positive effects of epigenetic reprogramming on human health.”_

Founded to repair tissues at a cellular level and innovate novel drug delivery systems, Turn Biotechnologies is in the preclinical phase of research and development. Their proprietary mRNA-based ERA™ technology aims to restore optimal gene expression by combating the impacts of aging on the epigenome. As a result, the ability of cells to prevent and treat diseases—and to heal or regenerate tissue—is reinstated, contributing to the fight against chronic diseases that presently have no cures. Their eTurna™ delivery platform ensures precise targeting of therapeutics to specific organs, tissues, and cell types.

With ongoing studies into tailored therapies in dermatology and immunology, Turn Biotechnologies is also developing treatments aimed at ocular health, osteoarthritis, and muscular issues. For more information, visit www.turn.bio.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.